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T;ヴｪWピﾐｪ ﾏWIｴ;ﾐｷゲﾏゲ ｷﾐ Iﾗｪﾐｷピ┗W 
デヴ;ｷﾐｷﾐｪ aﾗヴ ﾐW┌ヴﾗSWｪWﾐWヴ;ピ┗W 
SｷゲW;ゲWゲ
Cognitive training (CT) is a label used to 
describe paper-and-pen or computerized 
exercises designed to engage a desired set 
of mental skills for the purpose of enhancing 
neurocognitive functioning. Although the 
literature on the topic is considerably rich 
(on PubMed, for the sole 2018, the use 
of cognitive training as title keyword 
returns 123 results), very few studies pose 
the fundamental question: How does CT 
┘ﾗヴﾆいざが ﾗヴが ﾏﾗヴW ヮヴWIｷゲWﾉ┞が さB;ゲWS ﾗﾐ ┘ｴｷIｴ 
Iﾗﾏヮ┌デ;ピﾗﾐ;ﾉ ﾏWIｴ;ﾐｷゲﾏゲ ┘ﾗ┌ﾉS Wﾐｪ;ｪｷﾐｪ 
in CT result into meaningful changes in 
ﾗ┌デIﾗﾏW ﾏW;ゲ┌ヴWゲいざ.  The overwhelming 
majority of the studies focus on treatment 
WqI;I┞ H┞ ﾏﾗSWﾉﾉｷﾐｪ ﾗ┌デIﾗﾏW ﾏW;ゲ┌ヴWふゲぶ ;ゲ 
; a┌ﾐIピﾗﾐ ﾗa CT ふWくｪくが ;ﾐ ;Iピ┗W CT IﾗﾐSｷピﾗﾐ 
┗Wヴゲ┌ゲ an active control condition), but do 
ﾐﾗデ SWゲIヴｷHW ｷﾐ SWデ;ｷﾉ デｴW W┝;Iデ ﾏWIｴ;ﾐｷゲピI 
reason why CT should have an effect in 
the first place (De Marco et al., 2014). 
Biological frameworks have been proposed 
[ i .e. ,  the hypothetical  role played by 
neurotrophic factors, synaptic connections 
and neuroplasticity (Castells-Sánchez et al., 
2019)] but these have been introduced as an 
a posteriori interpretation, not as a driving 
principle for the design of the exercises.
From a merely clinical viewpoint, biological 
explanations are not necessarily of central 
importance. In fact, it is normal for clinicians 
;ﾐS IﾉｷﾐｷI;ﾉ ヴWゲW;ヴIｴWヴゲ デﾗ ヮヴｷﾗヴｷピ┣W HWﾐWgデゲ 
デﾗ ヮ;ピWﾐデゲ ﾗ┗Wヴ デｴW ﾏWIｴ;ﾐｷゲピI SWゲIヴｷヮピﾗﾐ 
of the instruments (once these have proven 
feasible, ethical and safe). After all, by the 
same logic, we still have not been able to 
clarify with rigorous detail by which exact 
biophysical mechanisms certain popular 
neuromodulation techniques operate, such 
as transcranial direct-current stimulation 
ふPWﾉﾉWピWヴ ;ﾐS CｷIIｴW│が ヲヰヱヴぶく
ISWﾐピa┞ｷﾐｪ デｴW ﾏWIｴ;ﾐｷゲﾏゲ CT ﾏｷｪｴデ ヴWﾉ┞ ﾗﾐ 
ｷゲ ﾗa ヮ;ヴピI┌ﾉ;ヴ ｷﾏヮﾗヴデ;ﾐIW aﾗヴ デｴW デヴW;デﾏWﾐデ 
of neurodegenerative diseases. This is 
by no means a trivial issue. A condition 
like Alzheimers disease, for instance, is 
Iｴ;ヴ;IデWヴｷ┣WS H┞ ﾏ┌ﾉピヮﾉW ヮ;デｴﾗヮｴ┞ゲｷﾗﾉﾗｪｷI;ﾉ 
mechanisms and it is against these that 
CT would have to be conceptualized. A 
prevalent hallmark in neurodegenerative 
diseases is the accumulation of abnormal 
protein forms and aggregates (Bayer, 2015). 
It is not simple to align the mechanisms 
of CT to these processes, as there is a 
fundamental theoretical distance between 
ヮWヮピSｷI ;ﾐS HWｴ;┗ｷﾗヴ;ﾉ ┗;ヴｷ;HﾉWゲ ヮヴW┗Wﾐピﾐｪ 
us from drawing direct causative links. 
Reflecting on this apparent theoretical 
ｷﾐIﾗﾏヮ;ピHｷﾉｷデ┞が ｴﾗ┘W┗Wヴが I;ﾐ HW ; ヮヴﾗS┌Iピ┗W 
exercise. In fact, it enables us to define a 
common ground on which both cellular 
and peptidic as well as behavioral variables 
can be transposed and investigated. This is 
the level of the neural systems deputed to 
information processing, already identified 
by the Imaging Genetics framework as a 
ﾏﾗヴW ヮヴﾗ┝ｷﾏ;デW HｷﾗﾉﾗｪｷI;ﾉ ﾉｷﾐﾆ デﾗ ｪWﾐWゲざ ;ﾐS 
;ゲ さ;ﾐ ﾗHﾉｷｪ;デﾗヴ┞ ｷﾐデWヴﾏWSｷ;デW ﾗa Iﾗｪﾐｷピﾗﾐが 
HWｴ;┗ｷﾗヴ ;ﾐS WﾏWヴｪWﾐデ ヮｴWﾐﾗﾏWﾐﾗﾐざ 
ふM;─;┞ Wデ ;ﾉくが ヲヰヰΒぶく Iデ ｷゲ ;デ デｴｷゲ ﾉW┗Wﾉ デｴ;デ CT 
can be devised as an instrument deputed to 
デ;ヴｪWデ ; ゲヮWIｷgI ﾏWIｴ;ﾐｷゲﾏく TｴW ヮﾗゲゲｷHｷﾉｷデ┞ 
of relying on cognitive operations to target 
the overall systems is also conveniently 
aligned with the use of neuroimaging as 
methodology to measure such systems. 
Techniques such as magnetic resonance 
imaging and positron emission tomography 
Wﾐ;HﾉW ヴWゲW;ヴIｴWヴゲ デﾗ ｷﾐ┗Wゲピｪ;デW ヮヴﾗヮWヴピWゲ 
ﾗa デｴW Hヴ;ｷﾐ デｴヴﾗ┌ｪｴﾗ┌デ ｷデゲ WﾐピヴW デﾗヮﾗｪヴ;ヮｴ┞く 
Oﾐ デｴｷゲ ﾐﾗデWが a┌ﾐIピﾗﾐ;ﾉ ﾏ;ｪﾐWピI ヴWゲﾗﾐ;ﾐIW 
imaging is particularly helpful because 
it allows the calculation of large-scale 
ｴ;WﾏﾗS┞ﾐ;ﾏｷI ﾐWデ┘ﾗヴﾆゲく Tｴｷゲ ｷゲ ヮ;ヴピI┌ﾉ;ヴﾉ┞ 
ヴWﾉW┗;ﾐデ aﾗヴ デｴW ゲデ┌S┞ ﾗa ﾐW┌ヴﾗSWｪWﾐWヴ;ピﾗﾐが 
because neurodegenerat ive diseases 
affect these networks with a large degree 
of selectivity (Seeley et al., 2009). As a 
result, focusing on whole-brain patterns of 
a┌ﾐIピﾗﾐ;ﾉ IﾗﾐﾐWIピ┗ｷデ┞ ヮヴﾗ┗ｷSWゲ ; デｴWﾗヴWピI;ﾉ 
ground on which disease mechanisms, 
training principles and test-retest outcome 
measurements are conveniently aligned 
(Fｷｪ┌ヴW ヱ).
B a s e d  o n  s u c h  a l i g n m e n t ,  w e  h av e 
proposed a CT hypothesis aimed at inducing 
synchronized activity of selected brain 
regions. Referring to Alzheimers disease 
as the diagnosis of interest, the underlying 
principle defining our hypothesis was that 
repeated task-related co-activation of 
multiple areas would result in increased 
resting-state functional connectivity among 
those areas (Martínez et al., 2013). On the 
basis that Alzheimers pathology selectively 
affects the brains default-mode network 
(Seeley et al., 2009; Pasquini et al., 2017), 
we designed a set of computerized exercises 
aimed at inducing co-activation of central 
hubs of this network. These exercises are 
centrally reliant on retrieval from semantic 
memory, but patients are also required to 
recruit a significant amount of executive 
resources in order to solve the tasks. The 
combined processing of semantic content, 
memory retrieval and executive control 
(each of which is supported by a specific 
デｴWﾗヴ┞どｷﾐaﾗヴﾏWS ヮ;─Wヴﾐ ﾗa Hヴ;ｷﾐ ;ヴW;ゲぶ ｷゲ ;デ 
the basis of the task-induced co-activation 
of multiple regions of the default-mode 
network including the hippocampus, lateral 
temporal cortex, posterior cingulate and 
medio-prefrontal cortex. After validating 
PWヴゲヮWIピ┗W
Aﾐﾐ;ﾉWﾐ; VWﾐﾐWヴｷゅが RｷII;ヴSﾗ M;ﾐI;が LｷﾐaﾗヴS FWヴﾐ;ﾐSWゲが Oﾉｷ┗Wヴ B;ﾐSﾏ;ﾐﾐが M;─Wﾗ DW M;ヴIﾗ
this principle in a cohort of healthy older 
adults (De Marco et al., 2016), we found 
that this approach up-regulates functional 
connectivity of the default-mode network 
in patients with mild cognitive impairment 
and a working diagnosis of prodromal 
Alzheimer s disease (De Marco et al. , 
2018), in favor of our hypothesis.  In further 
support of the construct validity of our CT 
conceptualization, we also found that the 
presence of a high load of white-matter 
hyperintensities (small lesions that impair 
inter-neuronal connectivity) is associated 
with significantly fewer modifications of 
network connectivity after CT (Bentham et 
;ﾉくが ヲヰヱΓぶく Tﾗ IﾗヴヴﾗHﾗヴ;デW デｴW WqI;I┞ ﾗa ﾗ┌ヴ 
network-based CT in a completely different 
Sｷ;ｪﾐﾗゲピI ゲIWﾐ;ヴｷﾗ ｷﾐ ┘ｴｷIｴが ｴﾗ┘W┗Wヴが ﾏｷﾉS 
cognitive impairment has also been linked 
to disruption of functional connectivity 
in the default-mode network (Hou et al., 
2016), we ran a pilot study in a group of 23 
ヮ;ピWﾐデゲ Sｷ;ｪﾐﾗゲWS ┘ｷデｴ P;ヴﾆｷﾐゲﾗﾐげゲ SｷゲW;ゲW 
ふPDぶ ;ﾐS ﾏｷﾉS Iﾗｪﾐｷピ┗W ｷﾏヮ;ｷヴﾏWﾐデが ﾗﾐ デｴW 
H;ゲｷゲ デｴ;デ ┌ヮどヴWｪ┌ﾉ;ピﾗﾐ ﾗa デｴW SWa;┌ﾉデどﾏﾗSW 
network would also translate into cognitive 
improvements in this diagnostic group. 
T┘Wﾉ┗W ﾗa デｴWゲW ヮ;ピWﾐデゲ ┘ｷデｴ ; Sｷ;ｪﾐﾗゲｷゲ ﾗa 
PD ;ﾐS ﾏｷﾉS Iﾗｪﾐｷピ┗W ｷﾏヮ;ｷヴﾏWﾐデ ┌ﾐSWヴ┘Wﾐデ 
the network-based CT as described in our 
previous studies with healthy older adult and 
prodromal Alzheimers disease participants 
(De Marco et al., 2016, 2018; Bentham et 
al., 2019). The remaining patients with PD 
and mild cognitive impairment acted as 
controls as they followed a pathway of care 
as usual.  These two groups were compared 
on behavioral outcome measures only, with 
assessments at baseline, after four weeks 
and at a longer-term follow-up, 6 months 
;ｦWヴ H;ゲWﾉｷﾐWく  
Iﾐ ゲ┌ヮヮﾗヴデ ﾗa ﾗ┌ヴ ｴ┞ヮﾗデｴWゲｷゲが ;ｦWヴ ヴ ┘WWﾆゲ ﾗa 
CT, improvement from baseline was observed 
;Iヴﾗゲゲ ﾏﾗゲデ Iﾗｪﾐｷピ┗W デWゲデゲ aﾗヴ デｴW デヴW;デﾏWﾐデ 
group (ASSｷデｷﾗﾐ;ﾉ Fｷｪ┌ヴW ヱ). Significant 
Iｴ;ﾐｪWゲ デｴ;デ ゲ┌ヴ┗ｷ┗WS IﾗヴヴWIピﾗﾐ aﾗヴ ﾏ┌ﾉピヮﾉW 
comparisons, however, were only detected 
for the Semantic Fluency test (P = 0.001), 
the Scales for Outcomes of PDCognition 
(P = 0.002) and the Trail Making test - part 
A (P = 0.003). In contrast, the participants 
in the control group showed no significant 
changes in any of the neuropsychological 
tests. The improvements observed in the PD 
デヴW;デﾏWﾐデ ｪヴﾗ┌ヮ ﾃ┌ゲデ ;ｦWヴ デWヴﾏｷﾐ;ピﾗﾐ ﾗa デｴW 
training (at 4 weeks) were not maintained 
after 6 months, but their scores remained 
higher than those recorded at baseline, 
suggesting time limited benefit in the 
absence of sustained stimulation of target 
mechanisms. Interestingly, in this group no 
significant improvements in the reaction 
times or accuracy scores were found over 
the course of the CT sessions, suggesting 
that the observed improvements in the 
group receiving CT were not dependent on 
improved motor performance. 
Aside from the small sample size that 
prevents  def in i te  and  genera l i zab le 
conclusions on the effectiveness of this 
CT for patients with PD and mild cognitive 
ｷﾏヮ;ｷヴﾏWﾐデが ﾏ;ﾃﾗヴ ﾉｷﾏｷデ;ピﾗﾐゲ ;ヴW ｷSWﾐピgWSぎ 
[Downloaded free from http://www.nrronline.org on Friday, November 6, 2020, IP: 90.196.174.249]
NEURAL REGENERATION RESEARCH̘Vol 16̘No.3̘March 2021̘501
Fｷｪ┌ヴW ヱ̘ TｴWﾗヴWピI;ﾉ aヴ;ﾏW┘ﾗヴﾆ ﾗa ﾏWIｴ;ﾐｷゲピI CT aﾗヴ ﾐW┌ヴﾗSWｪWﾐWヴ;ピ┗W SｷゲW;ゲWゲく 
Although the pathological processes of diseases such as Alzheimers disease or frontotemporal lobar 
SWｪWﾐWヴ;ピﾗﾐ ;ヴW ﾐﾗヴﾏ;ﾉﾉ┞ SWgﾐWS ;デ デｴW IWﾉﾉ┌ﾉ;ヴ ﾉW┗Wﾉ ふWくｪくが ;HWヴヴ;ﾐデ SWヮﾗゲｷピﾗﾐ ﾗa ﾏｷゲaﾗﾉSWS ヮヴﾗデWｷﾐゲが 
ﾐW┌ヴ;ﾉ ｷﾐ｡;ﾏﾏ;ピﾗﾐが ｷﾏヮ;ｷヴWS IWﾉﾉ┌ﾉ;ヴ ﾏWデ;Hﾗﾉｷゲﾏぶが ｷデ ｷゲ ｷﾏヮﾗヴデ;ﾐデ デﾗ Wゲデ;Hﾉｷゲｴ ; デｴWﾗヴWピI;ﾉ ;ﾉｷｪﾐﾏWﾐデ 
between disease and treatment mechanisms. This can be achieved by focusing on the large-scale brain 
ゲ┞ゲデWﾏゲが ┘ｴｷIｴ ｴ;┗W HWWﾐ ヮヴﾗ┗Wﾐ デﾗ ゲｴﾗ┘ SｷヴWIデ IﾗﾐﾐWIピﾗﾐゲ ┘ｷデｴ Hﾗデｴ SｷゲW;ゲW ﾏWIｴ;ﾐｷゲﾏゲ ;ゲ ┘Wﾉﾉ ;ゲ 
ﾐW┌ヴﾗヮゲ┞IｴﾗﾉﾗｪｷI;ﾉ a┌ﾐIピﾗﾐゲ デｴ;デ ;ヴW ;デ デｴW H;ゲｷゲ ﾗa CTく MﾗヴWﾗ┗Wヴが デｴW aﾗI┌ゲ ﾗﾐ Hヴ;ｷﾐ ゲ┞ゲデWﾏゲ Wﾐ;HﾉWゲ 
デｴW ;ﾉｷｪﾐﾏWﾐデ ﾗa デWゲデどヴWデWゲデ ﾗ┌デIﾗﾏW ﾏW;ゲ┌ヴWゲ ゲ┌Iｴ ;ゲ ヮﾗゲｷデヴﾗﾐ Wﾏｷゲゲｷﾗﾐ デﾗﾏﾗｪヴ;ヮｴ┞ ﾗヴ a┌ﾐIピﾗﾐ;ﾉ 
MRI ふデｴW ﾉ;─Wヴ ;ﾉﾉﾗ┘ｷﾐｪ デｴW SｷヴWIデ ﾏW;ゲ┌ヴW ﾗa デWゲデどヴWデWゲデ Iｴ;ﾐｪWゲ ｷﾐ ┘ｴﾗﾉWどHヴ;ｷﾐ ゲ┞ゲデWﾏｷI ヮ;─Wヴﾐゲ ﾗa 
a┌ﾐIピﾗﾐ;ﾉ IﾗﾐﾐWIピ┗ｷデ┞ぶく CTぎ Cﾗｪﾐｷピ┗W デヴ;ｷﾐｷﾐｪく
first, the absence of MRI data limits our 
margin of interpretation in this specific 
diagnostic sample; second, and more in 
general, concurrent neurovascular factors 
may impact on mechanisms and treatment 
response. On this note, the inclusion 
of  mult ip le  MRI  sequences in  future 
investigations may support a more robust 
ｷﾐデWヴヮヴWデ;ピﾗﾐ ﾗa gﾐSｷﾐｪゲく
In conclusion, these findings corroborate 
t h e  e v i d e n c e  t h a t  m e c h a n i s t i c  C T 
aimed at inducing changes in functional 
connectivity of neural systems is effective 
in supporting performance gains in the 
presence of neurodegeneration. Central 
to this framework is the identification of 
treatment mechanisms. Our proposition is 
that a network-based approach is suitable 
for aligning disease pathology, treatment 
mechanisms, cognitive functioning and 
test-retest outcomes on the common 
theoretical ground of neural systems. We 
argue that the definition of such strong 
theoretical rationale confers considerable 
;S┗;ﾐデ;ｪW ｷﾐ Iﾗﾏヮ;ヴｷゲﾗﾐ デﾗ ﾏﾗヴW ヮヴ;ｪﾏ;ピI 
clinical studies that are solely interested 
in the effect of CT and often conceive 
CT as a simple symptomatic form of 
treatment (i.e., memory difficulties, then 
memory exercises). Non-pharmacological 
ｷﾐデWヴ┗Wﾐピﾗﾐゲ I;ﾐ HW ; ヮﾗ┘Wヴa┌ﾉ ｷﾐゲデヴ┌ﾏWﾐデ 
in the treatment of neurodegenerative 
diseases, yet are often tacitly regarded 
as subsidiary, auxiliary tools to be used 
alongside a main recognized form of 
treatment that usually consists of one 
or more medications. Pharmacological 
treatments are seen as the natural 
avenue to counteract cognitive decline in 
neurodegenerative diseases because they 
target disease mechanisms in a direct way, 
ｷくWくが デｴWヴW ｷゲ ; SｷヴWIデ I;┌ゲ;ピ┗W ﾉｷﾐﾆ HWデ┘WWﾐ 
the drug and the brain. In order to see CT 
approaches become a primary therapeutic 
option it is necessary to follow the same 
rationale and define CT approaches that 
address specific disease mechanisms either 
directly or indirectly. For this reason, we 
argue that a transition from a symptom-
driven to a mechanism-driven approach 
to CT will enable this underdeveloped 
field of research to progress and become 
central for the development of treatment 
options against cognitive decline due to 
ﾐW┌ヴﾗSWｪWﾐWヴ;ピ┗W SｷゲW;ゲWゲく
Aﾐﾐ;ﾉWﾐ; VWﾐﾐWヴｷゅが RｷII;ヴSﾗ M;ﾐI;が 
LｷﾐaﾗヴS FWヴﾐ;ﾐSWゲが Oﾉｷ┗Wヴ B;ﾐSﾏ;ﾐﾐが 
M;─Wﾗ DW M;ヴIﾗ
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